Vol 2, No 3 (2009)
Prace poglądowe
Published online: 2009-10-29
Problemy terapeutyczne w leczeniu chorych z błoniastym kłębuszkowym zapaleniem nerek
Forum Nefrologiczne 2009;2(3):141-149.
Abstract
Nefropatia błoniasta jest jedną z najczęstszych przyczyn
zespołu nerczycowego u osób dorosłych. Przebieg
choroby jest bardzo różnorodny - od łagodnego
do szybkiej progresji w kierunku niewydolności
nerek. Obecnie trwają poszukiwania najlepszego
algorytmu terapeutycznego dla tej postaci kłębuszkowego
zapalenia nerek. Do tej pory ustaloną pozycję w leczeniu immunosupresyjnym ma połączenie
glikokortykoidów i chlorambucilu lub cyklofosfamidu.
Poszukiwane są schematy leczenia równie skuteczne,
lecz obarczone mniejszą liczbą działań niepożądanych.
Keywords: nefropatia błoniastazespół nerczycowyleczeniechlorambucilcyklofosfamidinhibitory kalcyneurynymykofenolan mofetilu
References
- Deegens JKJ, Wetzels JFM. Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy. Minerva Urol Nefrol. 2005; 57(3): 211–236.
- Klinger M, Krajewska M. Niezapalne choroby kłębuszków nerkowych. In: Książek A, Rutkowski B. ed. Nefrologia. Wydawnictwo Czelej, Lublin 2004: 270–286.
- Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant. 1997; 12(3): 418–426.
- Czekalski S, Oko A. Leczenie błoniastego kłębuszkowego zapalenia nerek. Nefrol Dial Pol. 2006; 10: 58–61.
- Adu D, Williams DG, Taube D, et al. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Q J Med. 1983; 52(208): 471–487.
- Ponticelii C. Membranous nephropathy. J Nephrol. 2007; 20(3): 268–287.
- Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008; 3(3): 905–919.
- Zucchelli P, Ponticelli C, Cagnoli L, et al. Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant. 1987; 2(2): 73–78.
- Donadio JV, Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988; 33(3): 708–715.
- Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993; 329(2): 85–89.
- Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol. 2003; 23(4): 406–411.
- Hofstra JM, Deegens JKJ, Willems HL, et al. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrol Dial Transplant. 2008; 23(8): 2546–2551.
- Branten AJW, du Buf-Vereijken PW, Klasen IS, et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol. 2005; 16(1): 169–174.
- Rostoker G, Durand-Zaleski I, Petit-Phar M, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron. 1995; 69(1): 20–28.
- Schieppati A, Ruggenenti P, Perna A, et al. Nonimmunosuppressive therapy of membranous nephropathy. Semin Nephrol. 2003; 23(4): 333–339.
- Rostoker G, Ben Maadi A, Remy P, et al. Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment. Nephrol Dial Transplant. 1995; 10(1): 25–29.
- Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995; 123(10): 754–762.
- Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001; 59(1): 260–269.
- Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003; 41(3): 565–570.
- Cameron JS. Membranous nephropathy: the treatment dilemma. Am J Kidney Dis. 1982; 1(6): 371–375.
- Cameron JS. Membranous nephropathy--still a treatment dilemma. N Engl J Med. 1992; 327(9): 638–639.
- Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis. 2004; 44(3): 562–566.
- Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005; 16(5): 1188–1194.
- Passerini P, Pasquali S, Cesana B, et al. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant. 1989; 4(6): 525–529.
- Ponticelli C, Glassock RJ, Ponticelli C, et al. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003; 23(4): 324–332.
- Troyanov S, Wall CA, Miller JA, et al. Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004; 66(3): 1199–1205.
- Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int. 2007; 72(12): 1429–1447.
- Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med. 1989; 320(4): 210–215.
- Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med. 1990; 74(274): 133–156.
- Ponticelli C, Zucchelli P, Passerini P, et al. A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy. New England Journal of Medicine. 1989; 320(1): 8–13.
- Ponticelli C, Passerini P, Salvadori M, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998; 9(3): 444–450.
- Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007; 18(6): 1899–1904.
- Chen Y, Schieppati A, Cai G, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004; 44(3): 385–401.
- Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008; 35(1): 100–105.
- Rutkowski B, Wielgosz A, Manitius J, et al. [Cyclophosphamide pulse therapy in patients with primary glomerulonephritis]. Przegl Lek. 2000; 57(11): 624–627.
- Cattran DC, Alexopoulos E, Heering P, et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant. 2006; 21(11): 3127–3132.
- Cattran DC, Appel GB, Hebert LA, et al. North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001; 59(4): 1484–1490.
- Kattah AG, Alexander MP, Angioi A, et al. Mentor Consortium group, Mayo Nephrology Collaborative Group. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73(1): 117–125.
- Goumenos DS, Kalliakmani P, Tsakas S, et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clinical Nephrology. 2004; 61(01): 17–24.
- Kranz B, Vester U, Büscher R, et al. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol. 2008; 23(4): 581–586.
- Praga M. Response to 'Tacrolimus in membranous nephropathy'. Kidney Int. 2008; 74(6): 824.
- Ballarin J, Poveda R, Ara J, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant. 2007; 22(11): 3196–3201.
- Arikan H, Koc M, Cakalagaoglu F, et al. Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol. 2008; 21(5): 713–721.
- Li X, Li H, Ye H, et al. Tacrolimus Therapy in Adults With Steroid- and Cyclophosphamide-Resistant Nephrotic Syndrome and Normal or Mildly Reduced GFR. American Journal of Kidney Diseases. 2009; 54(1): 51–58.
- Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009; 53(5): 760–769.
- Miller G, Zimmerman R, Radhakrishnan J, et al. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis. 2000; 36(2): 250–256.
- Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007; 50(2): 248–256.
- Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008; 52(4): 699–705.
- Klinger M, Durlik M. Zastosowanie MMF w pierwotnych kłębuszkowych zapaleniach nerek. Nefrol Dial Pol. 2009; 13: 67–70.
- Fervenza FC. Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer? Clin J Am Soc Nephrol. 2009; 4(6): 1017–1019.
- Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol. 2006; 1(4): 738–748.
- Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009; 4(6): 1083–1088.
